Ibex Medical Analytics Raises $38 Million to Accelerate Adoption of AI-powered Cancer Diagnostics in Pathology

11 Mar, 2021

Ibex Medical Analytics Raises $38 Million to Accelerate Adoption of AI-powered Cancer Diagnostics in Pathology
Photo by Alex Knight on Unsplash

– Ibex Medical Analytics announced a $38m Series B financing round led by Octopus Ventures and 83North, with additional participation from aMoon, Planven Entrepreneur Ventures and Dell Technologies Capital, the corporate venture arm of Dell Technologies.
– Ibex transforms cancer diagnosis by harnessing unique artificial intelligence (AI) and machine learning technology at an unprecedented scale.
– The company’s Galen™ platform supports physicians and providers to improve diagnostic accuracy and efficiency, and enables development of new AI tools for precision medicine in oncology.
– Pathologists play a crucial role in the detection and diagnosis of disease, with their assessment being vital for correct treatment decisions in cancer care.
– However, a rise in cancer prevalence and advances in personalized medicine have resulted in growing diagnostic complexity that significantly increases pathologists’ workloads.

Analytics Artificial Intelligence Asia Health Diagnostics Machine Learning
Crunchbase icon

Content report

The following text will be sent to our editors: